Monday, August 17, 2020

Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations

In a Phase II trial a combination targeted therapy achieved a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.

from Top Health News -- ScienceDaily https://ift.tt/317NlC5
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Only 13 % know: The one-minute self-exam that could save young men’s lives

A new survey shows most Americans wrongly think testicular cancer is an older man's issue, despite it most commonly affecting men aged 2...